Previous 10 | Next 10 |
2023-06-05 12:18:29 ET Cerus ( NASDAQ: CERS ) said on Monday that it has been awarded an additional $8.7M contract amendment to a $9.1M contract by the U.S. Department of Defense (DoD) Industrial Base Analysis and Sustainment ( IBAS ) program. Source: Press Release ...
Additional $8.7 million funding to support advancement towards FDA registration and full-scale product commercialization Cerus Corporation (Nasdaq: CERS) today announced that it has been awarded an additional $8.7 million contract amendment to the original $9.1 million contract by the U...
2023-05-24 13:33:04 ET In its preliminary annual 2023 Russell indexes reconstitution, a total of 164 companies will be added and 319 deleted from the Russell microcap index. Following notable healthcare companies will be added and deleted from Russell microcap index: Notable additio...
2023-05-10 15:41:43 ET Summary Today, we put medical device concern Cerus Corporation in the spotlight. Cerus has some current challenges, which management believes are temporary. Sales growth is projected to accelerate significantly in FY2024. Too early to buy the signi...
2023-05-04 21:10:08 ET Cerus Corporation (CERS) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Jessica Hanover – Vice President-Corporate Affairs Obi Greenman – President and Chief Executive Officer Vivek Jayaraman ...
2023-05-04 16:09:47 ET Cerus press release ( NASDAQ: CERS ): Q1 GAAP EPS of -$0.09 misses by $0.01 . Revenue of $38.48M (-10.6% Y/Y) beats by $1.47M . Reiterating 2023 Product Revenue Guidance The Company expects full-year 2023 product revenue will be in th...
Reiterating Full-Year 2023 Product Revenue Guidance Range of $165-170 Million Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2023. Recent highlights include: First quarter 2023 total revenue of $38.5 million was compris...
Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2023 financial results will be released on Thursday, May 4, 2023, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss t...
Cerus Corp (CERS) Q4 2022 Earnings Conference Call February 28, 2023, 16:30 ET Company Participants Joel Trujillo - Senior Director, IR William Greenman - President, CEO & Director Vivek Jayaraman - COO Kevin Green - VP, Finance & CFO Carol Moore - SVP,...
Cerus press release ( NASDAQ: CERS ): Q4 GAAP EPS of -$0.08 misses by $0.02 . Product revenue of $44.03M (+10.4% Y/Y) beats by $0.56M . Reiterating Full-Year 2023 Product Revenue Guidance Range of $165-170 Million For further details see: Cerus GAAP...
News, Short Squeeze, Breakout and More Instantly...
Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2024 financial results will be released on Thursday, August 1, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discu...
Cerus Corporation (Nasdaq: CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain an...
Symposium and Abstracts Highlight Data from Real-world Implementation and Utilization of INTERCEPT Platelets and Plasma as well as from Red Blood Cell and LED Illuminator Programs Cerus Corporation (Nasdaq:CERS) today announced a lunch symposium and selection of abstracts at the 38 th...